Ligand-biased and probe-dependent modulation of chemokine receptor CXCR3 signaling by negative allosteric modulators

ChemMedChem

Volumn 10, Issue 3, 2015, Pages 566-574

  Bernat, Viachaslau ^a,c   Brox, Regine ^a   Heinrich, Markus R ^a   Auberson, Yves P ^b   Tschammer, Nuska ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Allosteric modulation; Chemokine receptor CXCR3; Ligand biased signaling; Probe dependence

Indexed keywords

3 [4 (BENZYLOXY)BUTOXY]PROPAN 1 OL; 4 (3 FLUOROPROPOXY)BUTANOIC ACID; 4 (4 FLUOROBUTOXY)BUTANOIC ACID; 4 [4 (BENZYLOXY)BUTOXY]BUTAN 1 OL; BETA ARRESTIN 2; CHEMOKINE RECEPTOR AGONIST; CHEMOKINE RECEPTOR CXCR3; N [1 [3(4 ETHOXYPHENYL) 4 OXO 3,4 DIHYDROPYRIDO[2,3 D]PYRIMIDIN 2 YL]ETHYL] 4 (3 FLUOROPROPOXY)N [(1 METHYLPIPERIDIN 4 YL)METHYL]BUTANAMIDE; QUINAZOLINONE DERIVATIVE; UNCLASSIFIED DRUG; [[4 (3 FLUOROPROPOXY)BUTOXY]METHYL]BENZENE; [[4 (4 FLUOROBUTOXY)BUTOXY]METHYL]BENZENE; BETA ARRESTIN; CXCL11 CHEMOKINE; HETEROCYCLIC COMPOUND; IMMUNOLOGIC FACTOR; LIGAND; RETINA S ANTIGEN;

ALLOSTERISM; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHROMATOGRAPHY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROGENATION; HYDROPHILICITY; LIPOPHILICITY; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; HEK293 CELL LINE; IMMUNOLOGY;

ALLOSTERIC REGULATION; ARRESTINS; AZA COMPOUNDS; CHEMOKINE CXCL11; HEK293 CELLS; HUMANS; IMMUNOLOGIC FACTORS; LIGANDS; QUINAZOLINONES; RECEPTORS, CXCR3; SIGNAL TRANSDUCTION;

EID: 84923362213     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201402507     Document Type: Article

References (43)

1. T. Kenakin, Trends Pharm. Sci. 20035, 24, 346-354.
2. T. P. Kenakin, A. Christopoulos, Nat. Rev. Drug Discovery 2013, 12, 205-216.
3. T. Kenakin, J. Pharmacol. Exp. Ther. 2011, 336, 296-302.
4. J. R. Groom, A. D. Luster, Immunol. Cell Biol. 2011, 89, 207-215.
5. A. Kouroumalis, R. J. B. Nibbs, H. Aptel, K. L. Wright, G. Kolios, S. G. Ward, J. Immunol. 2005, 175, 5403-5411.
6. R. A. Colvin, G. S. V. Campanella, J. Sun, A. D. Luster, J. Biol. Chem. 2004, 279, 30219-30227.
7. S. Rajagopal, D. L. Bassoni, J. J. Campbell, N. P. Gerard, C. Gerard, T. S. Wehrman, J. Biol. Chem. 2013, 288, 35039-35048.
8. S. Lacotte, S. Brun, S. Muller, H. Dumortier, Ann. N. Y. Acad. Sci. 2009, 1173, 310-317.
9. T. L. Sørensen, M. Tani, J. Jensen, V. Pierce, C. Lucchinetti, V. A. Folcik, S. Qin, J. Rottman, F. Sellebjerg, R. M. Strieter, J. L. Frederiksen, R. M. Ransohoff, J. Clin. Invest. 1999, 103, 807-815.
10. I. Salomon, N. Netzer, G. Wildbaum, S. Schif-Zuck, G. Maor, N. Karin, J. Immunol. 2002, 169, 2685-2693.
11. W. W. Hancock, B. Lu, W. Gao, V. Csizmadia, K. Faia, J. a. King, S. T. Smiley, M. Ling, N. P. Gerard, C. Gerard, J. Exp. Med. 2000, 192, 1515-1520.
12. J. Pan, M. D. Burdick, J. a. Belperio, Y. Y. Xue, C. Gerard, S. Sharma, S. M. Dubinett, R. M. Strieter, J. Immunol. 2006, 176, 1456-1464.
13. T. C. Walser, S. Rifat, X. Ma, N. Kundu, C. Ward, O. Goloubeva, M. G. Johnson, J. C. Medina, T. L. Collins, A. M. Fulton, Cancer Res. 2006, 66, 7701-7707.
14. M. Krauthausen, S. L. Ellis, J. Zimmermann, M. Sarris, D. Wakefield, M. T. Heneka, I. L. Campbell, M. Müller, Am. J. Pathol. 2011, 179, 2346-2359.
15. M. Krauthausen, S. Saxe, J. Zimmermann, M. Emrich, M. T. Heneka, M. Müller, J. Neuroinflammation 2014, 11, 109.
16. M. Müller, S. Carter, M. J. Hofer, I. L. Campbell, Neuropathol. Appl. Neurobiol. 2010, 36, 368-387.
17. D. P. Widney, Y. Hu, A. K. Foreman-Wykert, K. C. Bui, T. T. Nguyen, B. Lu, C. Gerard, J. F. Miller, J. B. Smith, Infect. Immun. 2005, 73, 485-493.
18. K. Berry, M. Friedrich, K. Kersey, M. J. Stempien, F. Wagner, J. J. van Lier, R. Sabat, K. Wolk, Inflammation Res. 2004, 53, S222.
19. M. Wijtmans, D. Verzijl, R. Leurs, I. J. P. de Esch, M. J. Smit, ChemMed- Chem 2008, 3, 861-872.
20. B. T. Andresen, Endocr. Metab. Immune Disord. Drug Targets 2011, 11, 92-98.
21. E. J. Whalen, S. Rajagopal, R. J. Lefkowitz, Trends Mol. Med. 2011, 17, 126-139.
22. S. Rajagopal, S. Ahn, D. H. Rominger, W. Gowen-macdonald, C. M. Lam, S. M. Dewire, J. D. Violin, R. J. Lefkowitz, Mol. Pharmacol. 2011, 80, 367-377.
23. D. Wootten, A. Christopoulos, P. M. Sexton, Nat. Rev. Drug Discovery 2013, 12, 630-644.
24. T. Kenakin, C. Watson, V. Muniz-Medina, A. Christopoulos, S. Novick, ACS Chem. Neurosci. 2012, 3, 193-203.
25. S. Rajagopal, K. Rajagopal, R. J. Lefkowitz, Nat. Rev. Drug Discovery 2010, 9, 373-386.
26. Z.-G. Gao, D. Verzijl, A. Zweemer, K. Ye, A. Göblyös, A. P. IJzerman, K. A. Jacobson, Biochem. Pharmacol. 2011, 82, 658-668.
27. A. Christopoulos, T. Kenakin, Pharmacol. Rev. 2002, 54, 323-374.
28. D. J. Scholten, M. Canals, M. Wijtmans, S. de Munnik, P. Nguyen, D. Verzijl, I. J. P. de Esch, H. F. Vischer, M. J. Smit, R. Leurs, Br. J. Pharmacol. 2012, 166, 898-911.
29. B. Nedjai, H. Li, I. L. Stroke, E. L. Wise, M. L. Webb, J. R. Merritt, I. Henderson, A. E. Klon, A. G. Cole, R. Horuk, N. Vaidehi, J. E. Pease, Br. J. Pharmacol. 2012, 166, 912-923.
30. G. O'Boyle, C. R. J. Fox, H. R. Walden, J. D. P. Willet, E. R. Mavin, D. W. Hine, J. M. Palmer, C. E. Barker, C. A. Lamb, S. Ali, J. A. Kirbya, Proc. Natl. Acad. Sci. USA 2012, 109, 4598-4603.
31. T. Kenakin, Nat. Rev. Drug Discovery 2005, 4, 919-927
32. V. Bernat, T. H. Admas, R. Brox, F. W. Heinemann, N. Tschammer, ACS Chem. Biol. 2014, 9, 2664-2677.
33. I. Kalatskaya, Y. A. Berchiche, S. Gravel, B. J. Limberg, J. S. Rosenbaum, N. Heveker, Mol. Pharmacol. 2009, 75, 1240-1247.
34. C. Watson, S. Jenkinson, W. Kazmierski, T. Kenakin, Mol. Pharmacol. 2005, 67, 1268-1282.
35. K. Maeda, H. Nakata, Y. Koh, T. Miyakawa, H. Ogata, Y. Takaoka, S. Shibayama, K. Sagawa, D. Fukushima, J. Moravek, Y. Koyanagi, H. Mitsuya, J. Virol. 2004, 78, 8654-8662.
36. J. C. Medina, M. G. Johnson, A.-R. Li, J. Liu, A. X. Huang, L. Zhu, A. P. Marcus (Tularik Inc.), US Pat. No. US2002/0169159 A1, 2002.
37. M. Johnson, A.-R. Li, J. Liu, Z. Fu, L. Zhu, S. Miao, X. Wang, Q. Xu, A. Huang, A. Marcus, F. Xu, K. Ebsworth, E. Sablan, J. Danao, J. Kumer, D. Dairaghi, C. Lawrence, T. Sullivan, G. Tonn, T. Schall, T. Collins, J. Medina, Bioorg. Med. Chem. Lett. 2007, 17, 3339-3343.
38. S. Storelli, D. Verzijl, J. Al-Badie, N. Elders, L. Bosch, H. Timmerman, M. J. Smit, I. J. P. de Esch, R. Leurs, Arch. Pharm. 2007, 340, 281-291.
39. T. J. Ritchie, S. J. F. Macdonald, Drug Discovery Today 2009, 14, 1011-1020.
40. S. E. Ward, P. Beswick, Expert Opin. Drug Discovery 2014, 9, 995-1003.
41. V. Bernat, M. R. Heinrich, P. Baumeister, A. Buschauer, N. Tschammer, ChemMedChem 2012, 7, 1481-1489.
42. J. Fröhlich, F. Sauter, C. Hametner, M. Pfalz, ARKIVOC 2009, 2009, 298-308.
43. O. H. Lowry, N. J. Rosebrough, L. Farr, R. J. Randall, J. Biol. Chem. 1951, 193, 265-275.